Category Archives: Business and Investments

Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marqibo(R) (vincristine sulfate liposomes injection) in refractory pediatric cancer. The five-year agreement will initially focus on a Phase 1 trial to evaluate the safety, preliminary efficacy, pharmacokinetic profile, and weekly dose of Marqibo in children and adolescents with refractory cancer. Following the Phase I trial, the Company and CCR plan a Read More >

Intarcia Therapeutics, Inc. presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes, which demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period.  Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.

MDRNA, Inc. (NASDAQ: MRNA) announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 11/624,630 covering an siRNA directed against a junctional adhesion molecule-1 (JAM-1) gene. The siRNA of the allowed claim has a broad array of potential applications, most notably as a therapeutic for the treatment of certain cancers, thrombosis, atherosclerosis, strokes, and hypertension; and enhances the delivery of drugs across the skin and the Read More >

Raptor Pharmaceuticals Corp. (“Raptor”) (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. (“TorreyPines”) (Nasdaq: TPTX) announced the completion of their merger. The combined company is named “Raptor Pharmaceutical Corp.” and will commence trading today on the NASDAQ Capital Market under the ticker symbol “RPTP.” Pursuant to NASDAQ’s regulations, for the first 20 trading days the ticker symbol will be “RPTPd”. The combined company will be headquartered in Novato, California and managed by Raptor’s existing management Read More >

LifeCycle Pharma A/S (CSE:LCP) announced positive results from a 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug to prevent rejection after organ transplantation. These new data demonstrated that LCP-Tacro tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Read More >